Synaffix

Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor. 25 September 2025 -- Amsterdam, The Netherlands and Seongnam-Si, Korea -- Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced...
Pivot Park, Curie Building Kloosterstraat 9 5349 AB Oss The Netherlands

+31-88-022-4505